Ipsen Biopharmaceuticals, Inc.
1 Main Street
Unit 700
Cambridge
MA
02142
United States
Tel: 617-679-8500
Website: https://www.ipsenus.com/
Email: talentacquisition@ipsen.com
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
593 articles about Ipsen Biopharmaceuticals, Inc.
-
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
6/14/2023
Ipsen announced that the U.S. Food and Drug Administration has accepted its supplemental new drug application Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin as a potential first-line treatment for metastatic pancreatic ductal adenocarcinoma.
-
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
6/14/2023
Ipsen announced that the U.S. Food and Drug Administration has accepted its supplemental new drug application Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin as a potential first-line treatment for metastatic pancreatic ductal adenocarcinoma.
-
The FDA has four target action dates this week for three supplemental approvals and one New Drug Approval.
-
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
5/26/2023
Ipsen announced that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the Committee for Medicinal Products for Human Use of the European Medicines Agency confirms the negative opinion given in January 2023.
-
Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases
5/17/2023
Ipsen announced that new data from its growing rare disease portfolio will be presented at the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, taking place in Vienna, Austria 17-20 May 2023.
-
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
4/27/2023
Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the first quarter of 2023.
-
Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs
4/24/2023
Ipsen, a global specialty-driven biopharmaceutical company, announced the appointment of Sandra Silvestri, M.D., Ph.D., as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective 5 May 2023.
-
Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs
2/15/2023
Ipsen, Université de Montréal and IRICoR announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program with potential oncology applications.
-
Ipsen presents strong full-year 2022 results and guidance for 2023
2/9/2023
Ipsen, a global specialty-driven biopharmaceutical company, presents its financial results for the year and the fourth quarter of 2022.
-
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
1/27/2023
Ipsen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended not to grant marketing authorization for investigational palovarotene as a treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva.
-
Phase III data showed Ipsen’s Onivyde boosted overall survival in metastatic pancreatic ductal adenocarcinoma.
-
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
1/20/2023
Ipsen (Euronext: IPN; ADR: IPSEY) today presented positive results from the pivotal Phase III NAPOLI 3 trial evaluating an investigational regimen of Onivyde® (irinotecan liposome injection), a long-circulating, liposomal topoisomerase inhibitor, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
-
Ipsen bolsters rare disease portfolio with acquisition of liver disease specialist Albireo.
-
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
1/9/2023
Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
-
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
12/23/2022
The U.S. Food and Drug Administration issued a Complete Response Letter regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation in people living with fibrodysplasia ossificans progressiva.
-
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
12/14/2022
Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced the termination of its collaboration agreements with AbbVie, Inc. and Ipsen BioPharm Limited.
-
Ipsen will seek a new approval for Onivyde as a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) after posting positive Phase III progression survival data.
-
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
11/9/2022
Ipsen announced the Phase III NAPOLI 3 trial of Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm.
-
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
10/27/2022
Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the year to date and the third quarter of 2022.
-
Ipsen hit another stumbling block in its bid for an FOP approval as the FDA's Endocrinologic and Metabolic Drugs Advisory Committee postponed its meeting on the NDA for palovarotene capsules.